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Abstract: The kidneys play key roles in the maintenance of homeostasis, including fluid balance,
blood filtration, erythropoiesis and hormone production. Disease-driven perturbation of renal
function therefore has profound pathological effects, and chronic kidney disease is a leading cause of
morbidity and mortality worldwide. Successive annual increases in global chronic kidney disease
patient numbers in part reflect upward trends for predisposing factors, including diabetes, obesity,
hypertension, cardiovascular disease and population age. Each kidney typically possesses more
than one million functional units called nephrons, and each nephron is divided into several discrete
domains with distinct cellular and functional characteristics. A number of recent analyses have
suggested that signaling between these nephron regions may be mediated by microRNAs. For this
to be the case, several conditions must be fulfilled: (i) microRNAs must be released by upstream
cells into the ultrafiltrate; (ii) these microRNAs must be packaged protectively to reach downstream
cells intact; (iii) these packaged microRNAs must be taken up by downstream recipient cells without
functional inhibition. This review will examine the evidence for each of these hypotheses and discuss
the possibility that this signaling process might mediate pathological effects.
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1. Introduction
The Kidneys
The kidneys are a pair of bean-shaped organs located within the retroperitoneal space, either side
of the spinal column. The left kidney is situated between vertebral levels T12 to L3, with the right
kidney resting slightly inferior, due to displacement by the liver [1]. In human adult males, each kidney
is approximately 11 cm in length, and weighs approximately 150 g.
Renal functions in the maintenance of homeostasis include the regulation of acid-base balance,
osmolality, blood pressure and extracellular fluid volume. In addition, the kidneys produce hormones,
including calcitriol, angiotensin, and aldosterone.
The functional unit of the kidney is the nephron (Figure 1). Each kidney possesses approximately
1.3 million nephrons and each nephron is composed of several regions: The Bowman’s capsule that is
intimately associated with the glomerulus in the renal corpuscle; the proximal convoluted tubule (PCT);
the loop of Henlé; the distal convoluted tubule (DCT) and the collecting duct.
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Figure 1. The nephron—the functional unit of the kidney. A different color is used to highlight each 
nephron domain. The direction of ultrafiltrate flow is shown with black arrows, bold arrows signify 
secretion of waste products (red) and solute reabsorption (green). PCT, proximal convoluted tubule; 
DCT, distal convoluted tubule. 
Blood filtration takes place in the Bowman’s capsule. The PCT, loop of Henlé, DCT and collecting 
duct are concerned with selective solute reabsorption and secretion of waste components between 
the ultrafiltrate and the circulation. The ultrafiltrate then leaves the collecting duct en route to the 
renal papilla and then the bladder, from which it is excreted as urine. This direction of flow from 
glomerulus through the nephron dictates the course taken by ultrafiltrate-borne microRNAs 
(miRNAs) and of any signaling mediated by these transcripts. 
Underlining the importance of the kidneys’ physiological roles during homeostasis, renal 
pathologies, such as chronic kidney disease, diabetic kidney disease, acute kidney injury, renal 
cancer, glomerulonephritis, and polycystic kidney disease, lead to widespread morbidity and 
mortality that place a significant burden on health services worldwide. 
A more complete understanding of the processes underlying communication within the kidney 
promises to provide novel targets for disease prevention and treatment strategies [2]. Here we will 
review the evidence for miRNA-mediated intra-nephron signaling and for pathological effects 
mediated by this mechanism. 
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2. microRNAs
2.1. Discovery and Evolutionary Conservation of microRNAs
microRNAs were first identified in 1993 [3,4] and are found in algae, viruses, plants, invertebrates,
and vertebrates [5–7]. miRNA-mediated silencing mechanisms show ancient evolutionary origins [8].
The sequences that give rise to miRNAs may be located in introns of protein coding genes, in exons
and introns of long noncoding RNAs and in intergenic regions [9]. miRNAs are single-stranded RNA
transcripts most often of ~22 nucleotides in length, with strong secondary structure motifs. Mature
miRNAs may be clustered into families based on their nucleotide sequences [5].
2.2. Biogenesis of miRNAs
As summarized in Figure 2 below, most miRNAs are transcribed by RNA polymerase II as
primary miRNAs (pri-miRNAs) that exceed 200 nucleotides in length. Pri-miRNAs are next cleaved
into 60–70 nucleotide hairpin precursor miRNAs (pre-miRNAs) by the Microprocessor multiprotein
complex, a dimer composed of RNAse III enzyme Drosha and double-stranded RNA binding protein
Pasha/DGCR8.
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Figure 2. Nuclear transcription and export of icroR As ( iRNAs), and their roles in translational
repression. RISC, RNA-induced silencing complex.
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Pre-miRNAs are exported from the nucleus to the cytoplasm by Exportin-5, where they are
processed by a second RNAse III enzyme, Dicer. Dicer cleavage results in the formation of mature
~22 nucleotide long miRNA/miRNA* duplexes with a guide strand and a passenger strand, denoted
here by an asterisk, which is degraded when the duplex divides. The guide strand associates with
several RNA binding proteins, including argonaute 2 (Ago2), to form the microribonuclear protein
(miRNP) complex known as the RNA-induced silencing complex (RISC) (Figure 2). The mature
miRNA may silence target gene expression via two mechanisms: Binding to a target messenger
RNA (mRNA) strand thereby preventing its translation and/or through promoting target mRNA
degradation. Biogenesis of miRNAs is reviewed in detail elsewhere [10].
By widespread regulation of target mRNA translation and subsequent protein expression,
miRNAs help modulate the physiological processes that maintain homeostasis. Dysregulated miRNA
expression has been reported in the pathophysiology of numerous diseases, including malignancies
and cardiovascular disease [11].
2.3. microRNAs in Kidney Health and Disease
Key roles for miRNAs have been reported in all types of renal cell, demonstrating their importance
in kidney development and the maintenance of homeostatic kidney physiology [12]. Aberrant miRNA
expression has been observed in renal diseases, including kidney cancer, acute kidney injury, end-stage
renal disease, diabetic nephropathy and polycystic kidney disease [13–20].
As described above, Dicer processes pre-miRNAs to mature miRNAs in canonical miRNA
biogenesis, but non-canonical miRNA synthesis pathways have also been described [21,22]. Germline
Dicer knockout in mice results in non-viability, reflecting the crucial importance of miRNAs in
development [23]. In the kidney, podocyte-specific Dicer knockout results in glomerular and proximal
tubular injury with accompanying proteinuria [24–26] with similar results for Drosha ablation [27].
By contrast, it has been reported that proximal tubular-specific Dicer knockouts result in normal
renal function and protection against renal ischemia-related injury, although in this model significant
residual miRNA expression was quantifiable [28]. Dicer’s miRNA-independent roles [29,30] might
also complicate interpretation of data from models employing Dicer deletion.
In order to propose miRNAs as communicators between segments of the nephron, renal cells
must demonstrate the capacity to release miRNAs, package them appropriately for protected transport
through the ultrafiltrate, and to take up functional miRNAs from the extracellular environment,
which are able to exert a phenotypic effect on the recipient cell.
Table 1 below presents data on selected miRNAs in kidney health and disease. We apologize
to those authors whose work we were unable to include, due to the volume of publications in
this area. Excellent and comprehensive recent reviews covering this area include Rong et al. [31],
and Gomez et al. [32].
Table 1. MiRNAs implicated in kidney disease pathologies. MCs, mesangial cells. DN,
diabetic nephropathy.
microRNA Up/Down-Regulationin Disease/Model Identified Target Disease/Model References
MiR-192
Up SIP-1 Mouse Model, MCs (human, rat, mouse) [33]
Down Zeb2 DN patient samples, ProximalTubule cells [34,35]
MiR-29c Up Sproutyhomolog-1/HIF1α Mouse Model, MCs (mouse) [36,37]
MiR-21
Up Smad7 Mouse Model, MCs (rat) [38]
Up PPARa Human Kidney Biopsy [39]
Up MMP-9, TIMP1 Mouse Model, MCs (rat) [40]
Down PTEN Mouse Model, Primary MCs (mouse) [41]
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Table 1. Cont.
microRNA Up/Down-Regulationin Disease/Model Identified Target Disease/Model References
MiR-215
Up CTNNBIP1 Mouse Model, Primary MCs (mouse) [37]
Down Zeb2 Mouse Model, Primary MCs and PTCs (rat) [35]
MiR-200b/c Up Zeb1/2 Mouse Model, MCs (mouse),Endothelial cells [42,43]
MiR-29b Down TGFBR Mouse Model [44]
MiR-216a Up PTENYbx1 Mouse Model, Primary MCs (mouse) [45]
MiR-25 Down NOX4 Human Biopsy, MCs [46]
MiR-29a Down COL4α1/2 Proximal Tubule cells [47]
3. Intra-Nephron microRNA Transport
3.1. Extracellular Vesicle Nomenclature
As discussed below, many reports describe the presence of extracellular vesicle-associated
and non-extracellular vesicle-associated miRNAs in body fluids. For the purposes of this review,
wherever possible we will use the definitions from the recent comprehensive review by van Niel and
colleagues [48]. Briefly, when extracellular vesicles (EVs) are formed by plasma membrane budding
they are referred to as microvesicles (MVs), and fall typically within the 50–500 nm size range, but may
be as large as 1 µm. A second population of EVs is generated within the lumen of multivesicular
endosomes. Fusion of these endosomes with the plasma membrane results in the release of this second
EV population, which are referred to as exosomes and typically range in size from 50–150 nm [48].
Nevertheless, the reader should be aware of significant inconsistencies in past use of the terms EV,
microvesicle and exosome, and the wide variety of methods that have been used in EV isolation.
Further details are not within the remit of this review and may be obtained from the cited sources.
Hypothesis 1. miRNAs are released into the upstream ultrafiltrate.
3.2. Cellular Release of microRNAs
To date, comparatively little data on intra-renal miRNA transport have been reported. However,
numerous cell types release EVs, including dendritic cells [49], lymphocytes [50,51], endothelial
cells [52,53], mast cells [54], epithelial cells [55] and tumor cells [56]. Consequently, EVs have been
found in a range of body fluids, including saliva [57], blood plasma [58], cerebrospinal fluid [59],
amniotic fluid [60], pleural fluid [61], and urine [62]. The work of Valadi and colleagues first described
the presence of RNAs, including miRNAs, in exosomes released by mast cells [63].
Proteomic profiling of human urinary exosomes has revealed the presence of proteins specifically
expressed in the following nephron segments: Glomerular podocytes, proximal tubule, thick ascending
limb of Henle, distal convoluted tubule, collecting duct, and transitional epithelia from the urinary
drainage system [60,62,64,65].
The above data support the hypothesis that renal cells release exosomes into the ultrafiltrate.
Hypothesis 2. Released miRNAs are sufficiently stable to reach downstream cells intact.
3.3. Extracellular microRNA Stability
As part of immune surveillance against viral infection, biological fluids, including urine, contain
highly active RNA-degrading ribonucleases [66–68]. Consistent with this, we found that synthetic
Caenorhabditis elegans miR-39 added to human urine was degraded very rapidly [69]. By contrast,
stability of cell-free endogenous miRNAs has been demonstrated in plasma, serum, urine and tissue
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culture medium, suggesting protection from endogenous ribonucleases [69–74]. miRNAs in the
extracellular space may be stabilized by association with EVs [69,75] (Figure 3), and a recent study has
comprehensively demonstrated the stability of EV-associated circulating miRNAs [76].
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However, extracellular miRNAs do not associate exclusively with EVs (Figure 3). Wang and
co-workers [77] exposed human cells to acute stress and analysed the culture medium. Subsequent
differential centrifugation revealed the presence of miRNAs in centrifugation pellets containing EVs
(referre t ereafter as EV-associated or EVA), and EV-free fractions ( on-EVA). Supporting these
findin , rroyo et al. [72] reported two distinct opulations of plasma-borne miRNAs:
EVA- i te ith vesicular ultracentrifugation fractions coll cted with painstaking
precision t t re, and non-EVA-miRNAs.
T i l also reported tha the majority of plasma miRNAs were non-EVA-miRNAs
associate it I co ponent Ago2 (Figure 2) [72]. Associati n of plasma non-EVA-miRNAs with
Ago1 [78] and go2 as also reported elsewhere [73,78]. Western blot analysis of both plasma and
conditioned cell culture media following ultrafiltration showed association of most non-EVA-miRNAs
with Ago2 [73], which is believed to confer stability and protection from degradation [69,72,79].
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Our laboratory is investigating the use of miRNAs in urine and other body fluids as kidney
disease biomarkers [14,18–20,34,80–82]. On the basis of the above studies, we analyzed human urine
for presence on EVA and non-EVA-miRNAs [69]. Using established and optimized ultracentrifugation
protocols for isolation of intact EVs [83], we showed association of miR-16 and miR-192 with exosomal
and non-exosomal EV fractions [69]. We then used RNA-immunoprecipitation to show association of
these miRNAs with AGO2 [69].
High-density lipoproteins (HDLs) have also been implicated in the transport of miRNAs in the
extracellular circulatory environment [84]. This relationship was first proposed following the finding
that purified HDL fractions from human plasma contained miRNAs [84]. Transmission electron
microscopy allowed visualization of immunoprecipitated miRNA-HDL complexes that were clearly
distinguishable from EVs [84]. This association has the potential to protect miRNAs from ribonuclease
activity, and these authors proposed that miRNA-HDL transport represented an alternative form of
intercellular signaling [84] a theme that has attracted considerable further attention [85]. Low-density
lipoprotein (LDL) fractions from human plasma also contain miRNAs, but LDLs are less robust
miRNA carriers than HDLs [84,85]. Consequently, LDLs have received less attention in the context
of miRNA transport. A new pipeline for systematic analysis of lipoprotein-associated miRNAs has
been developed to expedite acquisition of this knowledge [86]. HDLs and LDLs are too large to pass
through the glomerular filtration barrier into the ultrafiltrate, and so are not predicted to play a part
in intraluminal miRNA transport within the nephron. However, it is conceivable that other, as yet
undiscovered, miRNA chaperones may be found in the ultrafiltrate.
Collectively, the above corroborate the hypothesis that miRNAs leaving nephron cells are
protected sufficiently from endogenous urinary ribonucleases.
Hypothesis 3. Downstream cells take up functional miRNAs from the ultrafiltrate.
3.4. Downstream Uptake of microRNAs
To date, much of the analysis of miRNA cellular uptake has focused on EVA-miRNAs. The process
of EV binding to target cells is likely directed by recipient cell surface receptors and EV membrane
protein composition: Following binding, internalization by endocytosis may be clathrin-mediated
or -independent, vesicular fate is dictated by their composition and target cell plasma membrane
structure. Once EVs have fused with the recipient cell, they elicit functional responses by receptor
activation at the recipient cell surface, and EV-miRNA and mRNA cargoes can activate responses
following internalization [48,63,87]. While the process of miRNA extracellular transport is now widely
accepted, the active/passive components of EV miRNA loading remain unresolved [88].
Exosomes were first implicated in the mediation of cell-to-cell communication via antigen
presentation [51]. Valadi and colleagues [63] subsequently showed the presence of exosome-associated
mRNAs and miRNAs from human and mast cell lines, and primary mouse mast cells. These authors
demonstrated de novo protein synthesis from transferred mRNA, suggesting that this represented a
novel mechanism of inter-cellular genetic exchange [63]. The concept of exosomes as novel mediators
of horizontal genetic transfer between cells soon expanded to include miRNAs synthesized in response
to viral infection, and mitochondrial DNA [89,90].
Numerous studies have described the regulation of target genes by EV-transported miRNAs.
Delivery of miR-126 in endothelial EVs derived from human aortic smooth muscle cells (HASMCs)
targeted regulator of G protein signaling 16 (RGS16) following transfer to human umbilical
vein endothelial cells (HUVECs), thereby inducing CXCL12 expression via CXCR4 [91]. Collino
and colleagues [92] showed that MVs delivered endogenous and synthetic miRNAs, and noted
downregulated expression of phosphatase and tensin homologue (PTEN), cyclin D1 and B cell
lymphoma 2 (Bcl-2), which they attributed to transferred miRNAs [92].
Zhang and co-workers [93] transfected fluorescently tagged synthetic miR-150 into THP-1
cells. MVs subsequently isolated from these cellswere then added to human dermal microvascular
Non-coding RNA 2018, 4, 30 8 of 13
endothelial cells and miR-150 transfer was observed, which resulted in reduced protein levels of
oncoprotein c-Myb. Communication between endothelial and HASMCs has been reported to confer
an atheroprotective effect [94]. Transcription factor Krüppel-like factor 2 (KLF2) induces expression
of miR-143 and miR-145. KLF2-transduced HUVECs produced EVs enriched in these miRNAs,
and subsequent co-culture with untreated HASMCs resulted in significantly decreased HASMC
expression of 6 miRNA target genes, including ETS transcription factor family protein ELK1 and matrix
metalloproteinase 3 (MMP3) [94]. A further study has shown reduced adipogenesis and lipogenesis in
porcine adipocytes as a result of PPAR-γ repression, driven by EV-shuttled miR-130b [95].
Of direct relevance to the kidney, a recent study presents time-lapse video evidence showing EVs
moving into renal proximal tubule cells by EV uptake, and also reports EV uptake by renal distal tubule
cells and collecting duct cells [96]. These authors also present evidence for functional transfer of PTC EVs to
distal tubule and collecting duct cells, positing that this provided proof of a proximal-to-distal intra-nephron
transfer between upstream proximal tubular cells and downstream recipients [96]. Furthermore, recent
sequence analysis has identified 276 mature miRNAs in urinary exosomes from healthy subjects and
observed enrichment of miR-10, miR-30 and let-7 families [97]. Cultured cells from human renal proximal
tubular cell line HKC-8 were then seen to take up urinary exosomes, which was followed by translational
repression of potassium channel ROMK and kinases SG1 and WNK1 [97].
Taken together, these studies provide strong supportive evidence for the uptake and function of
EVA-miRNAs by renal and other cells. Comparatively little attention has so far been paid to transfer of
functional non-EVA-miRNAs. As discussed above, there is strong evidence for HDL-mediated miRNA
transport in the circulation, and non-EVA-miRNAs are readily detectable in urine. The potential for
alternate non-EVA-miRNA transport and signaling mechanisms in paracrine miRNA signaling within
the nephron is an important area for future study.
4. Conclusions
The experimental studies detailed above provide strong support for the hypothesis that
endogenous miRNAs function as intra-nephron communicators. Key roles for miRNAs in disease
processes in the kidney are emerging. A complete understanding of intra-nephron miRNA transport
and function might permit the use of relevant miRNAs as biomarkers. Such biomarkers are intended
to provide a non-invasive method of measuring response to treatment in a patient with kidney disease,
or a mechanism by which likely response to treatment could be predicted. MiRNAs are also entering
testing as direct targets of therapy, and as a potential therapy approach themselves. Understanding the
mechanisms by which miRNAs are protected, packaged and taken up by target cells in the nephron
may provide valuable insights for novel approaches to miRNA therapy.
5. Patents
T.B. and D.J.F. are inventors for patent WO/2017/129977 Chronic Kidney Disease Diagnostic.
Author Contributions: M.J.T. performed the corresponding literature search, wrote a draft version of the
manuscript and created the corresponding figures. T.B. revised and edited the manuscript. D.J.F. revised
the final version of the manuscript.
Funding: This work was funded by a Knowledge Economy Skills Scholarship award to M.J.T., and Kidney Research
UK project grant award RP44/2014. The Wales Kidney Research Unit is funded by Health and Care Research Wales.
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